The Alvan R. Feinstein Page

Alvan R. Feinstein is the role model for nitpicking

In their litigation, the anti-smokers pawned off a "Proposed study by Alvan R. Feinstein, M.D. of the natural course and post-therapeutic outcome of cancers of the lung, larynx and rectum" as evidence of supposed wrongdoing, when it is really evidence of how their own stooges cheated the tobacco companies by producing irrelevant tripe.

Plaintiff's Exhibit 052B, "Proposed Study by Alvan R. Feinstein..." / UCSF (pdf, 2 pp)

Its much-hyped progenitor article, "Necropsy evidence of detection bias in the diagnosis of lung cancer" (Arch Intern Med 1986 Sep;146(9):1695-1698) was funded by the Robert Wood Johnson Clinical Scholars Program. The Robert Wood Johnson Foundation happens to be the leading funder of anti-smoking studies among the foundations. The numbers of missed diagnoses were inconsequential, and needless to say the study did nothing to challenge the orthodoxy of chemical carcinogenesis. "Incidence, prevalence and evidence" (Am J Med 1987 Jan;82(1):113-123; no abstract), another purported piece of evidence against the tobacco industry, was funded by the RWJF Clinical Scholars Program as well.

Feinstein / Arch Intern Med 1986 / UCSF (pdf, 4 pp)
Feinstein - Arch Intern Med 1986 abstract / PubMed
Feinstein / Am J Med 1987 / UCSF (pdf, 11 pp)

Feinstein wants $233,000 the first year and $252,000 the second year from the CTR to expand the study to include colon cancer, gallstones and coronary artery disease as well as lung cancer. James F. Glenn of the CTR inexplicably believes that Feinstein's study "suggests that lung cancer may not be directly linked to smoking." He thinks the project should have high priority, and gives it "an A for merit and A for relevance." But he thinks the budget should be reduced. And Henry T. Lynch's memo concurs, as does Bernard V. O'Neill Jr. of Shook, Hardy & Bacon..

Glenn Feb. 2, 1988 / UCSF (pdf, 1 p)
HT Lynch Feb. 16, 1988 UCSF (pdf, 2 pp)
O'Neill April 19, 1988 / UCSF (pdf, 2 pp)

Patrick M. Sirridge of Shook, Hardy & Bacon, praised another Feinstein research proposal, August 31, 1990. "By all accounts, Dr. Feinstein remains very active in the field of clinical epidemiology. His work is frequently cited and often generates scientific debate in both medical and epidemiological circles. Dr. Feinstein's recent research on the underdiagnosis of lung cancer, based on autopsy data, is a good example." It's a good example of a big deal about nothing. But he expects another $276,140.

Shook, Hardy & Bacon re Feinstein research proposal, 1990 / UCSF (pdf, 2 pp)

At the Rose Congressional hearing, Feinstein addressed only trifling issues regarding secondhand smoke and lung cancer. Statistical significance, confidence intervals, strength and consistency of association, dose-response and meta-analysis are not the key defect of those studies. Confounding by infection is that defect. This is the issue that the anti-smokers have conspired to ignore and repress all these years, and Feinstein's showmanship has helped them continue to misdirect attention to all the wrong places.

Feinstein - Rose Hearings / UCSF (pdf, 38 pp)

Feinstein is on the Medical Advisory Board of the Gairdner Foundation, a Canadian clone of the Lasker Foundation. It is part of that elite little ruling clique who are continually handing out awards and prizes to each other, no others need apply. Feinstein himself was awarded in 1993.

The Gairdner Foundation

Feinstein received $12, 241,644 from the Robert Wood Johnson Foundation between July 1974 and May 2001 for RWJF's Clinical Scholars Program at Yale University.

Clinical Scholars Program funding to Feinstein / Robert Wood Johnson Foundation

In Memoriam: Yale Expert in Clinical Research Methods, Alvan R. Feinstein. Yale News Release, Oct. 30, 2001; and: Influential physician Dr. Alvan Feinstein dies. Yale Bulletin & Calendar 2001 Nov 2;30(9).

News Release, Oct. 30, 2001 / Yale University
Feinstein Dies / Yale Bulletin & Calendar 2001

Assorted Feinstein studies

More Lung Cancer but Better Survival*. Implications of Secular Trends in "Necropsy Surprise" Rates. Charles K. Chan, Carolyn K.Wells, Michael J. McFarlane, Alvan R. Feinstein. Chest 1989 Aug;96(2):291-296.

Chan et al., Chest 1989 / UCSF (pdf, 7 pp)

<= Back to The Robert Wood Johnson Foundation
<= Back to The CTR

cast 04-02-06